DxS to provide AstraZeneca with companion diagnostic
This article was originally published in Clinica
Personalised medicine firm DxS is to provide its TheraScreen EGFR29 mutation kit to AstraZeneca as a companion diagnostic for the latter’s Iressa (gefitinib) cancer drug. TheraScreen will be used to test for the 29 most common mutations in a patient’s epidermal growth factor receptor (EGFR) gene in order to identify their eligibility for treatment with Iressa, which is designed to treat non small cell lung cancer. The CE-marked TheraScreen platform is based on DxS’ real-time PCR technology and also runs a K-RAS mutation test. TheraScreen can detect low levels of mutant genes in a background of wild type genomic DNA and provide results in less than three hours, according to Manchester, UK-based DxS. Financial terms of the deal were not disclosed.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals